Recombinant Human IL-17A Biotinylated Protein, CF

Measured by its binding ability in a functional ELISA. Biotinylated Recombinant Human IL‑17/IL‑17A (Catalog # BT7955B) binds to Recombinant Human IL-17RA/IL-17R Fc Chimera Protein (177-IR) with a ED50 of 2.00‑20.0 ng/mL.

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human IL-17A Biotinylated Protein, CF Summary

• Additional Information: Biotinylated
• Details of Functionality: Measured by its binding ability in a functional ELISA. Biotinylated Recombinant Human IL‑17/IL‑17A (Catalog # BT7955B) binds to Recombinant Human IL-17RA/IL-17R Fc Chimera Protein (Catalog # 177-IR) with a ED₅₀ of 2.00-20.0 ng/mL.
• Source: Human embryonic kidney cell, HEK293-derived human IL-17/IL-17A protein
  Gly24-Ala155
• Accession #: Q16552.1
• N-terminal Sequence: Gly24
• Structure / Form: Disulfide-linked homodimer
  Biotinylated via amines
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 15.1 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 12-25 kDa, under reducing conditions.

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in HCl with Trehalose.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 100 µg/mL in sterile 4 mM HCL.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human IL-17A Biotinylated Protein, CF

• CTLA8
• CTLA-8
• CTLA8cytotoxic T-lymphocyte-associated serine esterase 8
• Cytotoxic T-lymphocyte-associated antigen 8
• IL17
• IL-17
• IL17A
• IL-17A
• IL-17Acytotoxic T-lymphocyte-associated protein 8
• IL-17CTLA-8
• IL17interleukin-17A
• interleukin 17 (cytotoxic T-lymphocyte-associated serine esterase 8)
• interleukin 17A

Background

Interleukin-17A (IL-17A), also known as CTLA-8, is a 15-20 kDa glycosylated cytokine that plays an important role in anti-microbial and chronic inflammation. The six IL-17 cytokines (IL-17A-F) are encoded by separate genes but adopt a conserved cystine knot fold (1, 2). Mature human IL-17A shares 60% amino acid sequence identity with mouse and rat IL-17A (3, 4). IL-17A is secreted by Th17 cells, gamma /δ T cells, iNKT cells, NK cells, LTi cells, neutrophils, and intestinal Paneth cells (2). It forms disulfide-linked homodimers as well as disulfide-linked heterodimers with IL-17F (5, 6). IL-17A exerts its effects through the transmembrane IL-17RA in complex with IL-17RC or IL-17RD (7, 8). Both IL-17RA and IL-17RC are required for responsiveness to heterodimeric IL-17A/F (7). IL-17A promotes protective mucosal and epidermal inflammation in response to microbial infection (9-12). It induces chemokine production, neutrophil influx, and the production of antibacterial peptides
(9-11). IL-17A/F likewise induces neutrophil migration, but IL-17F does not (11). IL-17A additionally enhances the production of inflammatory mediators by rheumatoid synovial fibroblasts and contributes to TNF-alpha induced shock (4, 13). In contrast, it can protect against the progression of colitis by limiting chronic inflammation (12). IL-17A encourages the formation of autoreactive germinal centers and exacerbates the onset and progression of experimental models of autoimmunity (14, 15).
IL-17A has been shown to exert either tumorigenic or anti-tumor effects (16, 17).

1. Gaffen, S.L. (2009) Nat. Rev. Immunol. 9:556.
2. Cua, D.J. and C.M. Tato (2010) Nat. Rev. Immunol. 10:479.
3. Yao, Z. et al. (1995) J. Immunol. 155:5483.
4. Fossiez, F. et al. (1996) J. Exp. Med. 183:2593.
5. Chang, S.H. and C. Dong (2007) Cell Res. 17:435.
6. Wright, J.F. et al. (2007) J. Biol. Chem. 282:13447.
7. Wright, J.F. et al. (2008) J. Immunol. 181:2799.
8. Rong, Z. et al. (2009) Cell Res. 19:208.
9. Cho, J.S. et al. (2010) J. Clin. Invest. 120:1762.
10. Liang, S.C. et al. (2006) J. Exp. Med. 203:2271.
11. Liang, S.C. et al. (2007) J. Immunol. 179:7791.
12. O’Connor Jr., W. et al. (2009) Nat. Immunol. 10:603.
13. Takahashi, N. et al. (2008) J. Exp. Med. 205:1755.
14. Hsu, H. et al. (2008) Nat. Immunol. 9:166.
15. Rohn, T.A. et al. (2006) Eur. J. Immunol. 36:2857.
16. Wang, L. et al. (2009) J. Exp. Med. 206:1457.
17. Kryczek, I. et al. (2009) Blood 114:357.

Publications for IL-17/IL-17A (BT7955B)(1)

Publication using BT7955B

• ER Goedken, MA Argiriadi, JD Dietrich, AM Petros, N Krishnan, SC Panchal, W Qiu, H Wu, H Zhu, AM Adams, PM Bodelle, L Goguen, PL Richardson, PF Slivka, M Srikumaran, AK Upadhyay, B Wu, RA Judge, A Vasudevan, SM Gopalakris, PB Cox, VS Stoll, C Sun Identification and structure-based drug design of cell-active inhibitors of interleukin 17A at a novel C-terminal site Scientific Reports, 2022-08-26;12(1):14561. 2022-08-26 [PMID: 36028520] (Bioassay, Human)

FAQs for IL-17/IL-17A (BT7955B). (Showing 1 - 2 of 2 FAQ).

1. I want to stain some T cell subsets (Th17 and Th1), do you have antibodies for that? I need for flow cytometer in sheep or goat.
   • Unfortunately, we have neither a CD4 antibody nor an IL-17 antibody that has been validated in sheep or goat, although if you would like to try one you would again be eligible for our Innovators Reward Program. Please contact us at innovators@novusbio.com with any questions regarding this program.
2. I'm looking to establish an ELISA for IL-17 and want your recommendation on which antibody pairs to buy. Least expensive ones, please. Also, I'd like the detection antibody to be fluorescently labeled.
   • Thank you for your patience while I reviewed our ELISA validated products for IL17. I was not sure what species you were going to be investigating, so I looked up our data for the human protein. If this is incorrect, just let me know and I can look up products for the species you will be working with. As for antibody pairs, we only had one set that have been tested together: Capture: NBP2-22531 Detection: NBP2-22532. The detection product is only available currently with a biotin conjugate. We can however offer custom conjugation for this product to any of our available conjugates. Please see the this link to see the available fluors. The typical fee for custom conjugation is usually about $80 additional. Once you know which fluor you would like, I can provide you with a quote. We do also offer several ELISA kits for this target (they typically employ HRP or Biotin detection systems, so I am not sure if they will work for your needs).

Bioinformatics

• Uniprot:
  • Q16552.1()